Crystalline forms, compositions and uses of PCSK9 inhibitors

Abstract

The present disclosure provides crystalline forms of compounds of formula (I), as well as pharmaceutically acceptable compositions thereof, methods for their preparation, and their use in methods for treating hypercholesterolemia and other conditions associated with PCSK9 activity (e.g., atherosclerosis, atherosclerotic cardiovascular disease, peripheral artery disease, cerebrovascular disease, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular and cardiometabolic diseases).

Images